Black phosphorus (BP) has attracted increasing attention for cancer therapy because of its good biocompatibility and biodegradability and high photothermal conversion efficiency. Here, we developed a photothermally maneuvered all-in-one nanoplatform based on liposome-stabilized BP for the triggered drug delivery and oxygen (O 2 )-self-generated photodynamic multiple therapy of cancer. In this work, the multifunctional liposome (MFL) with the targeting ligands and imaging units was prepared and then assembled onto the surface of BP to form the sandwich-structured BP@MFL nanoplatform, which may efficiently improve the stability of BP in the aqueous solution. In order to achieve chemotherapy and in situ self-generation of O 2 , both resveratrol (RV) as an anticancer drug and catalase (CAT) as a O 2 -evolving agent were loaded on the BP surface before the treatment with the MFL. The obtained all-in-one nanoplatform (RV/CAT-BP@MFL) can recognize and selectively enter into cancer cells by the targeting ligands (folate) and then release the loaded RV and CAT under the near-infrared (NIR) laser irradiation due to the photothermal conversion effect of BP, which can be also applied for the photothermal therapy of cancer. The released RV can realize the chemotherapy of cancer. Moreover, free CAT may catalyze the decomposition of endogenous hydrogen peroxide high-expressed in tumor sites into O 2 , which can relieve tumor hypoxia and enhance the photodynamic treatment efficiency of BP. In vitro and in vivo experiments demonstrated that the all-in-one nanoplatform achieved the photothermally maneuvered drug delivery and synergistically O 2 -self-enriched photodynamic multiple therapy and thus enhanced dramatically the suppression of tumor growth. We believe that the all-in-one theranostic nanoplatform possesses substantial potential for clinical translation.
INTRODUCTION
Cancer remains one of the deadliest diseases affecting mankind. 1, 2 Over the past decades, tremendous efforts have been made to fight against cancer. 3 However, in current "onemedicine-fits-all" cancer treatment, it is easy to delay the best timing of treatment and make patients suffer from unnecessary side effects because of the complexity and heterogeneity of cancer. 4 The limits of the conventional cancer treatment approaches have heralded the urgent need for personalized medicine. 5, 6 As one of the most promising strategies in personalized medicine, nanotheranostics have been developed by integrating imaging and therapeutic functions into a single nanoplatform, which can not only achieve precise disease diagnosis but also apply an on-the-spot therapy. 7−11 The utilization of nanotheranostics enables the detection of targets, noninvasive monitoring of drug distribution, and the evaluation of therapeutic responses, through which various functionalities can be realized, such as improvement of pharmacokinetics, minimization of off-target toxicity, maximization of therapeutic efficacy, and adjustment of the individualized treatment in real time, thus improving the outcomes and safety of patients. 12−15 Various two-dimensional (2D) nanomaterials with versatile physicochemical properties have been prepared to achieve the simultaneous diagnosis and therapy of cancer, including carbon-based nanomaterials (e.g., graphene, GO, and rGO), 16 −18 layered double hydroxides, 19 transition metal oxides (e.g., MnO 2 ), 20 or transition metal dichalcogenides (e.g., MoS 2 and WS 2 ). 21, 22 Black phosphorus (BP), a new member of the family of 2D nanomaterials, has been discovered to be an interesting alternative to graphene owing to its easy fabrication, tunable and direct energy band gap, innate biocompatibility, and biodegradability. 23 The puckered lattice configuration of BP nanosheets offers a very high surface to volume ratio, which endows them with high cargo loading capacities. 24 Therefore, a BP-based delivery platform has been demonstrated as a highly efficient drug delivery system (DDS) of various functional molecules, including siRNA, 25 doxorubicin, 26 chlorin e6, 27 gold nanoparticles, 28 and Fe 3 O 4 /Au nanoparticles. 29 Meanwhile, BP nanosheets can be utilized as a photothermal transducing agent for photothermal therapy (PTT), which be can attributed to their large near-infrared (NIR) extinction coefficient and high photothermal conversion efficiency. 30 Additionally, BP nanosheets have been applied as an efficient photosensitizer for singlet oxygen ( 1 O 2 ) generation due to their rich surface atoms which can perform as the active centers and low recombination rates of electron−hole. 31 More importantly, the final degradation products of BP nanosheets are nontoxic phosphate or phosphonate, which preferentially confers the "safer-by-design" concept in the biomedical field. 32 Despite such unique and fascinating characteristics, BP is still in its infancy. A fundamental challenge hampering the practical applications of BP nanosheets is their vulnerability to rapid degradation in aqueous media, which will cause a deterioration of their intrinsic biofunctions. 33−35 To date, several strategies have been introduced to improve the ambient stability of BP nanosheets, including heteroatom deposition, 36−38 covalent functionalization, 39−42 and protective layer coating. 43−45 However, most of these strategies are not suitable to be used as a DDS. Excessively stabilized BP nanosheets may prevent the DDS from biodegradation even after completing its therapeutic mission. 46 Moreover, the synthetic methods are somewhat complicated and time-consuming, restricting massive production and clinical translation. Therefore, a simple and versatile stabilization strategy is urgently needed to promote biomedical applications of BP.
Herein, we designed a multifunctional, BP-based all-in-one theranostic nanoplatform for photothermally maneuvered drug delivery and O 2 -self-supplied photodynamic multiple therapy ( Figure 1 ). In our design, free BP nanosheets were first functionalized successively with resveratrol (RV) serving as an anticancer drug and catalase (CAT) acting as an O 2 -evolving agent by physical adsorption for achieving chemotherapy and the enhanced photodynamic therapy (PDT) of cancer. In order to improve the stability of the functionalized BP in an aqueous system, especially under physiological conditions, liposomes were employed to enwrap the BP surface because of their good biocompatibility and biodegradability. To further obtain the targeting and fluorescence imaging abilities, liposomes were modified with the broad-spectrum targeted ligand (folate) and the commercially available fluorescent dye (atto647) to prepare the multifunctional liposome (MFL) before the encapsulation process. The obtained all-in-one nanotheranostic (RV/CAT-BP@MFL) could selectively enter folate receptor-overexpressing cancer cells through the folatemediated endocytosis. Under the guidance of the fluorescence imaging, the NIR laser could be accurately focused on the tumor site at the best timing. Upon NIR irradiation, the photothermal effect of the BP nanosheets core of RV/CAT-BP@MFL not only resulted in the local temperature rise of the tumor site to effectively kill the cancer cells but also disrupted the coated layer of liposome and triggered the release of the loaded RV and CAT from the BP nanosheets to the cytoplasm of cancer cells. The released RV induced apoptosis through the mitochondria pathways. 47 The free CAT could catalyze the decomposition of endogenous hydrogen peroxide (H 2 O 2 ) overexpressed by cancer cells into O 2 in situ. The sustained self-sufficiency of O 2 promoted the PDT efficiency of BP nanosheets under hypoxic tumor microenvironments. Consequently, a versatile theranostic nanoplatform was developed 
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Article by integrating the CAT, RV, and BP nanosheets and MFL to simultaneously achieve the following purposes: (i) targeted delivery for transporting loaded cargo to tumor sites specifically, (ii) NIR laser controlled release for minimizing premature cargo leakage before reaching the cancer sites, (iii) NIR laser-responsive degradation for avoiding undesirable long-term side effects, (iv) self-sufficiency of O 2 for alleviating hypoxia in solid tumors, (v) fluorescence imaging for better therapeutic planning, and (vi) the combination of chemotherapy, PTT, and PDT for synergistic therapeutics. To our best knowledge, such an all-in-one nanosystem is still rare in the literature.
EXPERIMENTAL SECTION
2.1. Synthesis of BP. The ultrathin BP nanosheets were prepared by following a previously reported liquid exfoliation protocol with minor modification. 48 Specifically, 25 mg of bulk BP was first ground by hand and then dispersed in 50 mL of NMP. The mixture solution was sonicated using an ultrasonic cell disruption system (300 W, ON/ OFF cycle: 4 s/2 s) for 12 h and then sonicated by a bath type sonicator (300 W) for another 12 h. The temperature of the sample solution was kept at 4°C by an ice bath to prevent oxidation. Next, the resulting brown suspension was centrifuged at 3000 rpm for 15 min to remove the residual unexfoliated bulk BP, and the supernatant was decanted gently for further use. Before use, the BP nanosheets were spun down for 20 min at 8000 rpm, and the precipitate was extensively washed with ddH 2 O to remove all traces of the organic solvent NMP.
2.2. Synthesis of MFL. The biotin/FA-PEG liposome was first synthesized by a modified thin film hydration method, as previously reported. 49 Briefly, the molar ratio of DOTAP, FA-PEG-DSPE, and biotin-PEG-DSPE was 8.5:1:0.5 (3 μmol in total). The mixture solution was dispersed in 3 mL of methanol/chloroform (1:2, v/v) solution in a round-bottom flask and dried in a rotary evaporator at 37°C under reduced pressure to form a thin lipid film on the inside wall of the flask. In order to remove any possible residual organic solvents, the lipid film was dried in a desiccator under vacuum overnight. The sample was hydrated with 3 mL of ddH 2 O for 10 min at 60°C and sonicated in an ultrasonic cleaning system for 10 min at 4°C.
Through using the streptavidin−biotin method, the above prepared biotin/FA-PEG liposome was modified with ATTO dyes to obtain the NIR fluorescence imaging capability. First, 3 μM SA was mixed with 3 mL of biotin/FA-PEG liposome (1 μmol mL −1 ) and gently stirred with a stirring bar at 37°C for 1 h to allow for efficient conjugation. Next, 30 μM ATTO was added to SA-biotin/FA-PEG liposome at 37°C for 1 h to finally obtain ATTO-SA-biotin/FA-PEG liposome. The resulting liposome suspension was dialyzed overnight using a dialysis bag (Spectrum Lab., Rancho Dominguez, CA) with a 10 000 molecular weight cutoff (MWCO) for removal of excess dyes. For the sake of simplicity, the as-obtained ATTO-SA-biotin/FA-PEG liposome was denoted as MFL.
2.3. Synthesis of BP@MFL. A total of 1 mL of fresh-obtained BP aqueous solution (200 μg mL −1 ) was mixed with 3 mL of the resulting MFL suspension (1 μmol mL −1 ) and sonicated for 2 h using an ultrasonic cell disruption system at a power of 60 W in an ice water bath. Uncoated liposome was removed by filtration using a centrifugal filter (MWCO 100 kDa, Millipore, Bedford, MA). The obtained BP@ MFL was suspended in a small volume of ddH 2 O and kept in storage at 4°C prior to use.
2.4. Synthesis of RV/CAT-BP@MFL. RV, CAT, and MFL were loaded onto BP nanosheets using the same procedure as the synthesis of BP@MFL with minor modification. In detail, 240 μL of RV ethanol solution (10 mg mL −1 ), 200 μL of CAT solution (35.8 mg mL −1 ), and 12 mL of MFL suspension (1 μmol mL −1 ) were added into 4 mL of a BP nanosheet suspension (0.2 mg mL −1 ). After sonication in an ice water bath for 2 h and stirring vigorously in the dark at 25°C overnight, the as-obtained RV/CAT coloaded and MFL-coated BP nanoplatform (RV/CAT-BP@MFL) was gathered by filtration by a centrifugal filter (MWCO 100 kDa, Millipore, Bedford, MA). CAT protein concentration was measured using a BCA protein assay kit. The amount of loaded CAT protein was calculated by subtracting the CAT left in the supernatant from the total protein added in loading process. To further determine the drug loading and encapsulation efficiency, the different concentrations of RV (50, 100, 150, and 200 μg mL −1 ) were loaded onto the RV/CAT-BP@MFL nanoplatform following the above-mentioned procedure. Next, the loading capacity and encapsulation efficiency were estimated using the formulas:
Loading capacity (%) mass of loaded RV mass of drug carrier RV BP@MFL 100%
Encapsulation efficiency (%) mass of loaded RV mass of added RV 100% = ×
(2) 2.5. Stability Evaluation. The BP, BP@MFL, and RV/CAT-BP@MFL the with the same amount of BP (0.2 mg mL −1 ) were dispersed in ddH 2 O or FBS, kept in opened polypropylene centrifuge tubes (Corning Inc., Corning, NY) and shaken at 37°C under moisture and aeration conditions. At designed time points (the 1st, 3rd, 5th, 7th, 9th, 11th, and 13th day), a 200 μL sample was pipetted out for UV−vis spectral analysis. Meanwhile, the samples were taken out for TEM imaging at 0, 1, and 13 days postincubation.
2.6. NIR-Controlled Release of RV/CAT-BP@MFL. The NIRcontrolled release experiment was conducted at 37°C on a horizontal shaker. In detail, 1 mg of RV/CAT-BP@MFL and 1 mL of doubledistilled water were well mixed in a microcentrifuge tube (1.5 mL). At predetermined time intervals (0, 50, 110, 170, 230, and 290 min), the sample was irradiated with a 780 nm laser (Beijing Hi-Tech Optoelectronic Co., China) at a power density of 0.6 W cm −2 for 10 min, and 0.2 mL of the release solution was pipetted out for analysis. After centrifugation at 12 000 rpm for 5 min, the absorption of RV in the supernatant was measured using a UV−vis spectrophotometer, and the RV concentration was calculated using a standard curve-based method. The release efficiency of RV was figured out by the follow formula:
Percentage of RV release (%) mass of released RV mass of loaded RV 100% = ×
After the measurements, the supernatant was put back to the release media to keep the constant volume. In order to investigate the responsibility of the NIR laser, the release behaviors were compared in the presence or absence of NIR irradiation. 2.7. Photothermal Performance of RV/CAT-BP@MFL. Samples with various concentrations of RV/CAT-BP@MFL (0, 62.5, 125, 250, 500, and 1000 μg of BP equiv mL −1 ) were irradiated with a 780 nm laser for 5 min at a power density of 0.6 W cm −2 , and the temperature variations were recorded at 1 min intervals.
2.8. Photodynamic Properties of RV/CAT-BP@MFL. DPBF was used as an indicator for 1 O 2 determination by the UV−vis spectroscopic measurements. Briefly, 15 μL of 2 mg mL −1 DPBF in ethanol solution was added to 1.5 mL of ddH 2 O, BP@MFL (100 μg mL −1 ), or RV/CAT-BP@MFL (400 μg mL −1 ). The samples were kept in a glovebox filled with nitrogen gas to mimic the tumor hypoxia. The mixtures were placed in the dark under constant stirring for 100 min to achieve a state of adsorption and desorption equilibrium. Afterward, H 2 O 2 (final concentration: 1 mM) was added into BP@MFL and RV/CAT-BP@MFL solution. Next, the samples were continuously irradiated with a 660 nm laser at a power density of 10 mW cm −2 for 15 min. At different time points (0, 3, 6, 9, 12, and 15 min), 200 μL of sample was pipetted out for UV−vis spectral analysis.
2.9. In Vitro Cellular Targeting Assays. The in vitro cellular targeting effect of RV/CAT-BP@MFL was investigated by a CLSM. The ATTO dye, which has been grafted onto RV/CAT-BP@MFL, was primarily adopted as the signal reporter. Specifically, MCF-10A,
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Article A549, and MCF-7 cells were incubated with RV/CAT-BP@MFL (200 μg mL −1 ) in 200 μL of serum-free culture medium for 30 min at 4°C, respectively. After washing twice with washing buffer, cells were stained with 10 μg mL −1 Hoechst-33342 for 10 min. Then, the medium was replaced with PBS. Finally, the fluorescence pictures were acquired by a CLSM (Hoechst-33342: Ex/Em = 355/460 nm, ATTO: Ex/Em= 633/675 nm).
2.10. Detection of Cellular Hypoxia. The intracellular level of O 2 was investigated by a commercially available O 2 sensing probe [Ru(dpp) 3 ]Cl 2 , which could be effectively quenched by O 2 . Briefly, the MCF-7 cells (1 × 10 4 cells per well) were planted onto a 96-well plate and incubated overnight. After this period, the medium was discarded and replaced by fresh culture medium containing PBS, BP@ MFL (50 μg mL −1 ), or RV/CAT-BP@MFL (200 μg mL −1 ). To induce cellular hypoxia, DFO (final concentration: 30 μM) was added. After incubation for 4 h, [Ru(dpp) 3 ]Cl 2 (final concentration: 20 μM) was carefully added and cultured for another 30 min. After rinsing with washing buffer, cell images were captured by using an inversed fluorescence microscope.
2.11. Generation of Intracellular 1 O 2 . The MCF-7 cells (1 × 10 4 cells per well) were planted onto a 96-well plate and incubated overnight. After this period, the medium was discarded and replaced by 200 μL of fresh culture medium containing PBS, BP@MFL (50 μg mL −1 ), and RV/CAT-BP@MFL solution (200 μg mL −1 ). Meanwhile, DFO (final concentration: 30 μM) was added to induce cellular hypoxia. After incubation for 4 h, DCFH-DA was added into the medium at a final concentration of 20 μM and cultured for another 30 min. Afterward the samples were illuminated with or without 660 nm laser (0.1 W cm −2 ) for 15 min as indicated. After rinsing with washing buffer, cells were imaged by an inversed fluorescence microscope.
2.12. In Vitro Cytotoxicity Assay. For determining synergistic antitumor efficacy of RV/CAT-BP@MFL, the CellTiter 96 cell proliferation (MTS) assays were used to assess the cell viability. Briefly, MCF-7 cells (1 × 10 4 cells per well) were first planted onto a 96-well plate in 180 μL of DMEM medium supplemented with 12% FBS and 100 IU mL −1 penicillin/streptomycin for 12 h. Subsequently, 20 μL of phosphate buffered saline (PBS), free RV (0.5 mg mL −1 ), BP@MFL (0.5 mg mL −1 ), RV-BP@MFL (1 mg mL −1 ), CAT-BP@ MFL (1.5 mg mL −1 ), or RV/CAT-BP@MFL (2 mg mL −1 ) was respectively added. Three duplicate wells were set for each sample. The cells were incubated at 37°C for 4 h. After fresh medium replacement, NIR laser irradiation was conducted as indicated. For PTT therapy, the cells were irradiated with a 780 nm laser at a power density of 0.6 W cm −2 for 5 min. For PDT therapy, the cells were irradiated with a 660 nm laser at a power density of 0.1 W cm −2 for 15 min. Next, the cells were cultured in a humidified incubator (37°C, 5% CO 2 ) for 24 h. After replacing the original culture medium with fresh medium, 20 μL of MTS reagent was pipetted into each well and cultured for another 4 h. Finally, the optical density (OD) at 490 nm was determined using a multidetection microplate reader. The cell viability was calculated according to the following equation:
where OD t was gained from the samples treated by various treatments. OD b was gained from the empty wells. OD c was gained from the samples without any treatment.
2.13. In Vivo Fluorescence Imaging. Tumor-bearing mouse models were constructed by subcutaneously implanting 1 × 10 6 cancer cells into the hind limb of each animal. Once the volume of tumor nodules exceeded 100 mm 3 , the mice were anesthetized with pentobarbital sodium. Time-lapse images of MCF-7 tumor-bearing mice were captured using an in vivo camera system after intravenous (i.v.) injecting of 200 μL of RV/CAT-BP@MFL (without folate) or RV/CAT-BP@MFL (0.8 mg mL −1 ).
2.14.
In Vivo Synergistic Therapy. The tumor-bearing mice were randomly allocated to 11 experimental groups: (i) PBS + 660/ 780 nm laser, (ii) BP@MFL, (iii) free RV, (iv) free DOX, (v) RV/ CAT-BP@MFL, (vi) CAT-BP@MFL + 660 nm laser, (vii) CAT-BP@MFL + 780 nm laser, (viii) RV/CAT-BP@MFL + 660 nm laser, (ix) RV/CAT-BP@MFL + 780 nm laser, (x) CAT-BP@MFL + 660/ 780 nm laser, and (xi) RV/CAT-BP@MFL + 660/780 nm laser. Various nanoplatforms were administered intravenously to the tumorbearing mice at a dosage of 2.2 mg kg −1 of body weight by RV or 2 mg kg −1 of body weight by BP. NIR laser irradiation was conducted as indicated. For photothermal therapy, the animals were exposed to a 780 nm laser (0.6 W cm −2 ) for 5 min at 1 h postinjection. While for PDT, the animals were illuminated with a 660 nm laser (0.1 W cm −2 ) for 15 min at 1.5 h postinjection. The temperature distribution in the tumor was measured by using an infrared thermal camera during the irradiation. The tumor size was monitored using a digital caliper at intervals of 1 day and calculated as Tumor volume length width 2
The relative tumor volume was calculated as V/V 0 , where V 0 was the initial volume. For evaluation of the potential side effects, the body weights were measured every other day. Animals were humanely sacrificed after 14 days, and the tumors were dissected and imaged. Meanwhile, major organs (heart, liver, spleen, lung, kidney, and tumor) were harvested for pathological analyses. For the hematoxylin and eosin (H&E) stained histology, the above-collected major organs were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 8 μm, stained with H&E, and observed under an inversed fluorescence microscope. 2.15. Hemolysis Assay. SD rat blood was centrifuged for 5 min at 3000 rpm and rinsed 5 times with PBS to obtain intact RBC. Next, 300 μL of RBC suspensions were respectively added into 300 μL of ddH 2 O (positive control), PBS (negative control), or RV/CAT-BP@ MFL with various concentrations. The sample was cocultured at 37°C for 24 h. After spinning down the RBC, the supernatant was carefully aspirated, and the absorbance values were read at 540 nm by a UV−vis spectrometer. The hemolysis ratio was calculated as follows:
where I t was gained from the absorbance of the supernatant in different concentrations of RV/CAT-BP@MFL. I pc was gained from the absorbance of the supernatant in ddH 2 O. I nc was gained from the absorbance of the supernatant in PBS. 2.16. Hematology and Biochemistry. The in vivo toxicity RV/ CAT-BP@MFL was evaluated by hematology and biochemistry examination. In brief, six healthy male SD rats (6 weeks old) were randomly divided into two groups (n = 3): (i) control group: i.v. injection of 200 μL of saline, and (ii) experimental group: i.v. injection of 200 μL of RV/CAT-BP@MFL (2 mg kg −1 by BP). Blood was collected after injection for 1, 3, and 7 days. A total of 100 μL of the obtained blood was collected into spray-dried K2EDTA tubes for hematological analysis. The residual blood was maintained overnight at 4°C and then centrifuged at 5000 rpm for 5 min to separate serum (200 μL) for the biochemistry assay.
2.17. Statistical Analysis. The one-way analysis of variance (ANOVA) statistical method was performed to evaluate the experimental data. 50 A value of 0.05 was selected as the significance level, and the data were indicated with (*) for p < 0.05, (**) for p < 0.01, and (***) for p < 0.001, respectively.
RESULTS AND DISCUSSION
3.1. Characterization of the Synthesized BP and BP@ MFL. The ultrathin BP nanosheets were synthesized from bulk BP crystals by the liquid-phase exfoliation method. 51 Transmission electron microscopy (TEM), high resolution transmission electron microscopy (HR-TEM), atomic force microscopy (AFM), and energy-dispersive X-ray (EDX) spectroscopy were employed to examine the morphology and chemical composition of the as-obtained BP nanosheets.
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Article Figure 2A showed a representative TEM image of BP. It could be seen that the nanosheets had ultrathin paper-like morphology. Clear lattice fringes were observed from the HR-TEM image ( Figure S1A ), and the interplanar spacing of 0.21 nm was assigned to the (013) plane of the BP crystal, which was consistent with previous reported lattice parameters of BP. 52 The corresponding fast Fourier transform (FFT) image ( Figure S1B ) suggested the single crystal nature of asobtained BP nanosheets. Additionally, AFM image ( Figure  S2A ) showed that BP nanosheets had a good monodispersibility with an average lateral size of 313 ± 115 nm. The thickness of BP nanosheets was determined to be 2.2 ± 0.4 nm by AFM ( Figure S2B ), which matched very well with the reported literature. 53 The EDX pattern ( Figure S3 ) revealed that the BP is mainly composed of P elements, and the existence of a small amount of O element may be due to the oxidation of phosphorus.
For the purpose of stabilizing BP nanosheets, selectively delivering payloads into cancer cells, and NIR fluorescence imaging, MFL was synthesized and assembled on the surface of BP nanosheets to form MFL-coated BP (BP@MFL). In brief, upon simple mixing, MFL tended to attach to the surface of the BP nanosheets ( Figure S4 ), which was probably due to electrostatic interaction between the positive charges of the MFL and the negative charges of the BP nanosheets. Afterward, with sonication treatment, the liposome broke and self-assembled into such a structure: the hydrophobic tails of phospholipids oriented toward the BP surface due to the hydrophobic feature of pristine BP, 54 while the hydrophilic headgroups of phospholipids fronted on the aqueous environments on both sides. TEM, HR-TEM, AFM, elemental mapping, dynamic light scattering (DLS), and ζ potential were employed to determine the feasibility of this coating method. Specifically, TEM images (Figure 2A ) confirmed that the as-prepared BP@MFL maintained 2D morphology. Both 
Article the HR-TEM images ( Figure S1C ) and the corresponding FFT results ( Figure S1D ) demonstrated that BP@MFL reserved the original crystalline features of the BP nanosheets after the MFL coating. The BP@MFL size measured by AFM ( Figure S2C ) was 256 ± 83 nm, and the minor decrease in the size was probably because of additional sonication during the MFL-coating process. Furthermore, the AFM images ( Figure  S2D) showed that a topological height of the as-prepared BP@ MFL was 5.9 ± 0.2 nm, which was roughly equal to the total thickness of BP (2.2 ± 0.4 nm) and the phospholipid bilayer (∼4 nm). 55 The elemental mapping ( Figure 2B) showed the excellent colocalization of three different elements in BP@ MFL (O and N elements from the surface coated MFL, P element from BP), indicating that MFL could be grafted onto the BP nanosheet surface successfully. The hydrodynamic size of this nanoplatform characterized by DLS was shown in Figure S5 . BP showed an average hydrodynamic size of 229 nm with polydispersity index (PDI) of 0.228, while the hydrodynamic size of the BP@MFL was raised to 255 nm (PDI: 0.018) after MFL coating (containing long chain PEG phospholipids). Meanwhile, the MFL grafting had a significant influence on the surface charge. In Figure 2C , BP had a ζ potential of −21.4 mV, whereas the ζ potential of BP@MFL increased to +30.4 mV because of the highly cationic MFL grafting (+38.3 mV).
After preliminary evaluation of the feasibility of MFL coating, the optical properties of the BP@MFL were determined by UV−vis absorption spectroscopy, fluorescence spectroscopy, and an in vivo fluorescence imaging system. As illustrated in Figure 2D , the BP@MFL exhibited broad and strong absorptions, indicating its potential as a photothermal conversion agent. At the same time, BP@MFL exhibited an absorption maximum at 644 nm corresponding to the characteristic absorption peak of atto647 (ATTO), which provided additional evidence for successful MFL coating (containing ATTO modified phospholipids). In addition, the fluorescence of loaded MFL was partially quenched by BP nanosheets (Figure S6 ), demonstrating strong interactions between BP and MFL. The fluorescence stability study of BP@ MFL was carried out by monitoring the variation of ATTO fluorescence at several time points. BP@MFL maintained more than 75% original fluorescence intensity after storing at 37°C for 7 days ( Figure S7 ), suggesting that BP@MFL could be applied as a promising fluorescence tracer.
3.2. Characterization of the Synthesized RV/CAT-BP@ MFL. Since BP nanosheets possessed a relatively high surface area, the potential loading ability of BP-based DDS was worth the expectation. In this work, we loaded the BP nanosheets with RV, an anticancer drug, and CAT, an O 2 -evolving agent for the development of multifunctional RV/CAT-BP@MFL. The RV/CAT-BP@MFL could be readily obtained through assembling the BP with RV, CAT, and MFL under sonication assistance. The concentration of CAT was quantified using the BCA Protein Assay Kit ( Figure S8 ), and the amount of immobilized CAT was estimated to be approximately 1.9 g g −1 BP. Moreover, the release of CAT could be conveniently controlled by the NIR laser irradiation ( Figure S9 ). Next, the UV−vis spectrum of RV/CAT-BP@MFL ( Figure S10 ) had a maximum absorption at 306 nm characteristic of RV, proving that RV molecules were successfully loaded onto RV/CAT-BP@MFL. Furthermore, the RV loading capacity and encapsulation efficiency were calculated by using a standard curve approach. Here, loading capacity was defined as the amount of RV loaded per unit weight of the drug carrier RV-BP@MFL, and encapsulation efficiency was calculated as the weight percentage of the RV loaded versus the amount added to the dispersion. As shown in Figure 2E , with the RV feeding concentration increasing, the loading capacity increased linearly. However, the excess feeding of RV would decrease the encapsulation efficiency of RV/CAT-BP@MFL ( Figure  S11 ). Based on the above data, we finally chose 150 μg mL −1 as the optimal feeding concentration, and the drug loading capacity and encapsulation efficiency of RV/CAT-BP@MFL were 52.9 ± 1.6% and 37.4 ± 3.0%, respectively.
3.3. Stability Study. We then evaluated the role of the MFL coating layer on the physiological stability of BP. Specifically, the BP and BP@MFL were dispersed in water and exposed to air for 13 days at the same concentration. Their absorption spectra were measured at an interval of 2 days. It was reported that degradation of BP depended on the reactions of the lone-pair electrons of P atoms (P 0 ) in BP and O 2 to form phosphorus oxide (P x O y ), and H 2 O facilitated conversion of P x O y to phosphate (PO 4 3− ). 56 When BP was dispersed in H 2 O, P x O y could be readily removed by H 2 O molecules to continuously expose fresh P 0 leading to accelerated degradation, resulting in a decline of its absorbance continuously. As shown in Figures 2F and S12 , during the initial dispersing, both the BP and the BP@MFL exhibited broad and strong absorptions. However, the absorbance intensity of BP decreased significantly with dispersion time. The absorbance (A) of BP at 450 nm decreased by ∼60.4% compared to the original value (A 0 ) at the 13th day. Conversely, the absorption intensity of BP@MFL was quite stable, and only ∼9.4% fluctuation in A/A 0 at 450 nm was observed throughout the testing period. Moreover, no obvious absorbance change of RV/CAT-BP@MFL (A/A 0 at 450 nm: ∼10.2%) was observed, demonstrating that the RV and CAT loading had little influence on the stability of BP@MFL. The reason for the enhanced stability of BP@MFL and RV/CAT-BP@MFL was that the interior BP was adequately protected from O 2 and H 2 O, owing to the compact coating layer of MFL. Interestingly, after RV/CAT-BP@MFL was exposed to the 780 nm laser, the nanosystem warmed up due to the photothermal effect of BP and became unstable again due to the collapse of coated MFL shells, which led to an ∼49.7% decrease in A/A 0 at 450 nm. Additionally, the improved stability of BP@MFL was further confirmed by TEM images (Figure S13 ). After 1 day, BP was observed with dense and large holes, and after 13 days, the morphology of BP was completely disrupted. However, BP@MFL maintained the integrity with negligible morphological changes throughout the whole period. The stability of RV/CAT-BP@MFL was investigated by incubation of BP and RV/CAT-BP@MFL in the fetal bovine serum (FBS) for different times. In Figure S14 , RV/CAT-BP@MFL exhibited less fluctuation in A/A 0 at 450 nm than BP (RV/CAT-BP@MFL, 19.7% versus BP, 64.5%) during the period, demonstrating the feasibility of MFL coating to avoid undesirable degradation of BP during circulation. Collectively, these findings revealed that a coating with MFL was an efficient strategy to prevent BP from rapid degradation for maintaining a sufficient therapeutic time window, highlighting its enormous potential for biomedical applications.
As a potential theranostic agent, it was necessary to investigate the colloidal stability of the nanoplatform in the stimulated body fluid. We compared the dispersibility of RV/ CAT-BP@MFL with BP in different solutions, including
Article phosphate-buffered saline (PBS), culture medium, and serum. As displayed in Figure S15 , the BP nanosheets were observed to be unstable and subjected to aggregation. Noteworthily, the RV/CAT-BP@MFL nanoplatform was well dispersed for more than 24 h. The excellent dispersion stability in the simulated biological environments suggested that RV/CAT-BP@MFL might be applied as a drug delivery system in vivo.
3.4. In Vitro NIR-Laser Triggered Drug Release, Photothermal Effect, and Photodynamic Property Study. The desired property of the drug carrier was that it could release payloads in a controllable manner. 57 In vitro drug release behavior was investigated using a 780 nm laser as a trigger. The light intensity was set to 0.6 W·cm −2 with an exposure time of 10 min (ON), followed by another 50 min under dark (OFF). As displayed in Figure 2G , without NIRlaser irradiation, RV release from RV/CAT-BP@MFL was slow. However, when the NIR laser was "ON", an interesting burst-like release of RV was significantly triggered, such as from 8.4% to 25.4% at 1 h. And the drug release ceased when the laser was "OFF". Additionally, the sequence of "ON/OFF" was repeated at 2, 3, 4, and 5 h, respectively. In this case, a similar burst-like release was observed, and the cumulative RV release from RV/CAT-BP@MFL finally reached 75.6%. Consequently, the RV release from RV/CAT-BP@MFL could be precisely controlled by the NIR-laser irradiation, which was mainly due to laser-induced hyperthermia.
To evaluate the photothermal effect of RV/CAT-BP@MFL, different concentrations of RV/CAT-BP@MFL were dispersed in aqueous solutions and exposed to 780 nm laser (0.6 W cm −2 ) for 5 min. In Figure 2H , the temperature of pure H 2 O slightly changed upon 780 nm laser irradiation (from 26.7 to 31.0°C). Contrarily, the temperature of RV/CAT-BP@MFL showed a significant concentration-and time-dependent temperature rising and achieved 44.8, 47.8, 52.4, 53.5, and 60 .3°C at different concentrations of RV/CAT-BP@MFL (62.5, 125, 250, 500, and 1000 μg BP equiv mL −1 , respectively). In addition, the temperature changes were visually monitored by an infrared thermal camera, and a similar temperature rise trend was observed as well ( Figure  S16) . Meanwhile, the photothermal conversion efficiency (η) was calculated to be 40.1% for RV/CAT-BP@MFL ( Figure  S17) . Also, there are no significant variations in photothermal performance of RV/CAT-BP@MFL ( Figure S18 ) during four heating and cooling cycles under 780 nm laser exposure. Together, the excellent photothermal property of RV/CAT-BP@MFL has been well-proved.
Furthermore, the photodynamic activity of RV/CAT-BP@ MFL was evaluated under 660 nm laser irradiation, using 1,3diphenylisobenzofuran (DPBF) as a 1 O 2 indicator. DPBF possessed a highly specific reactivity toward the produced 1 O 2 and was oxidized subsequently to colorless ortho-dibenzoylbenzene, resulting in a decline of its absorbance at 410 nm. 58 As shown in Figures 2I and S19 , there was no change in the intensity of the DPBF absorption band with 660 nm laser irradiation alone (15 min, 10 mW cm −2 ). Meanwhile, irradiation of the BP@MFL and BP@MFL + H 2 O 2 solution decreased 21.0% and 16.4% of DPBF respectively, indicating the inferior photodynamic efficiency of BP@MFL. However, upon the CAT loading and H 2 O 2 adding, the absorption of DPBF was decreased by 33.8% in the solution of RV/CAT-BP@MFL + H 2 O 2 , which was much higher than that of RV/ CAT-BP@MFL (24.1%) under the same BP concentration. The enhanced photodynamic activity of RV/CAT-BP@MFL was likely because of the elevated levels of O 2 from the catalytic H 2 O 2 decomposition by loaded CAT of RV/CAT- 
Article BP@MFL. The above results concluded that RV/CAT-BP@ MFL could be served as an enhanced PDT agent.
3.5. In Vitro Targeted Cellular Uptake, Overcoming Tumor Hypoxia, and Cytotoxicity Assay. Delivery of the loaded therapeutic cargo to the target site with high efficiency and specificity was essential for the DDS. 59 The successful grafting of folate to the RV/CAT-BP@MFL and its binding specificity were investigated by monitoring the fluorescence of ATTO dyes. The RV/CAT-BP@MFL nanoplatform was incubated with nontumorigenic MCF-10A, folate receptorpositive MCF-7, and folate receptor-negative A549 cells, respectively. The cells were cultured at 4°C for 30 min to maximize the targeting effect of RV/CAT-BP@MFL and minimize nonspecific uptake. As shown in Figure 3A , the confocal laser scanning microscopy (CLSM) images demonstrated that RV/CAT-BP@MFL-treated MCF-7 cells had strong red fluorescence of ATTO in the cytoplasm, implying efficient cellular uptake of the nanoplatform. Contrarily, MCF-10A and A549 cells displayed only a weak red fluorescent signal. Moreover, the cellular uptake of RV/CAT-BP@MFL was blocked when the MCF-7 cells were preincubated with free folate. The obvious difference in fluorescence intensity confirmed the folate receptor-mediated targeting ability of RV/ CAT-BP@MFL.
Since CAT could catalyze the breakdown of cellular H 2 O 2 to generate O 2 , we exploited the synergy between CAT and BP to achieve self-sufficiency of O 2 and then enhance the therapeutic efficiency of PDT. First, MCF-7 cells were preincubated with the hypoxia-mimetic agent deferoxamine (DFO) to mimic the hypoxic situation of solid tumors. 60 The successful induction of hypoxia in MCF-7 cells was proven by the increasing fluorescence intensity of the O 2 probe [Ru(dpp) 3 ]Cl 2 ( Figure  3B ). 61 Subsequently, the fluorescence of [Ru(dpp) 3 ]Cl 2 was decreased upon adding RV/CAT-BP@MFL, demonstrating the ability of RV/CAT-BP@MFL to attenuate hypoxia in vitro. Furthermore, to evaluate the efficacy of an O 2 -self-generating PDT by RV/CAT-BP@MFL, 2′,7′-dichlorofluorescein diacetate (DCFH-DA) was used to evaluate the intracellular 1 O 2 production with or without CAT loading. 62 As shown in Figure 3C , for the cells treated with BP@MFL, the intracellular fluorescence intensity was as low as the control group, suggesting the limited PDT effects of BP@MFL under 
Article tumor hypoxia. In contrast, for the RV/CAT-BP@MFL group, the intracellular fluorescence intensity was ∼6 times higher than that in the control group, which indicated that RV/CAT-BP@MFL possessed high generating efficiency of 1 O 2 in the hypoxic environment. Therefore, the in situ self-sufficiency of O 2 by RV/CAT-BP@MFL could attenuate tumor hypoxia via degrading H 2 O 2 and thus enhance the outcome of PDT.
Taking advantage of the targeted delivery, efficient photothermal effect, and O 2 -self-generating photodynamic activity, an in vitro multiple therapy of RV/CAT-BP@MFL was carried out. MCF-7 cells were incubated with free RV, BP@MFL, RV-BP@MFL, CAT-BP@MFL, or RV/CAT-BP@MFL in the presence or absence of NIR irradiation (780 nm, 0.6 W cm −2 , 5 min; 660 nm, 0.1 W cm −2 , 15 min). The methyl thiazolyl tetrazolium (MTT) assay was performed to evaluate the cell viability after different treatments ( Figure 3D ). For the cells treated with BP@MFL alone, about 95.59% of the cells were still alive, demonstrating that the drug carrier BP@MFL had excellent biocompatibility. For the cells treated with RV-BP@ MFL (chemotherapy), a cell viability of 65.57% was observed, which was lower than that of free RV (74.45%). This could be attributed to the protection effects of RV-BP@MFL and the enhanced cellular uptake. Noteworthily, the dual-combination treatments (chemotherapy/PTT: 25.52%; chemotherapy/ enhanced PDT: 43.91%; PTT/enhanced PDT: 28.46%) offered more efficient therapeutic effects against tumor cells than monotherapies (chemotherapy: 65.57%; PTT: 45.88%; enhanced PDT: 58.12%). Most importantly, the cell viability was only 5.23% for the triple-combined chemotherapy/PTT/ enhanced PDT treatment, which was much lower than that of dual-modal synergistic therapies. Collectively, these results demonstrated that the RV/CAT-BP@MFL exhibited a high synergistic effect, and the triple-modal synergistic therapy obviously had the best therapeutic efficiency in vitro.
3.6. In Vivo NIR Fluorescence Imaging-Guided Synergistic Therapy. Because of the complicated in vivo environment, it was necessary to investigate biodistribution of RV/CAT-BP@MFL in a tumor-bearing animal model. Mice bearing MCF-7 tumors with an overexpressed folate receptor were administrated with RV/CAT-BP@MFL or RV/CAT-BP@MFL (without folate) via the intravenous (i.v.) route. In vivo fluorescence imaging was collected by recording ATTO fluorescence. As displayed in Figure 4A ,B, compared with the RV/CAT-BP@MFL (without folate) group, the fluorescence 
Article signal of the RV/CAT-BP@MFL group began to appear in the tumor region quickly at 5 min postinjection and reached the highest contrast and clearly indicated the target tumor site at 60 min postinjection. Further, the major organs and tumor tissue were isolated for ex vivo imaging at 120 min postinjection ( Figure 4C,D) . Notably, a higher tumor site signal was observed in the mice injected with RV/CAT-BP@ MFL than with RV/CAT-BP@MFL (without folate). The efficient tumor accumulation of the nanoplatform was owing to folate receptor-mediated active targeting effects. Additionally, ex vivo imaging showed strong fluorescence in the liver and kidney, demonstrating the effective catabolism of RV/CAT-BP@MFL.
Inspired by the excellent synergistic therapeutic effect in vitro and fascinating in vivo tumor accumulation results, we then conducted animal experiments to test the possibility of RV/CAT-BP@MFL for in vivo therapy of cancer. In detail, tumor-bearing BALB/c mice were randomly allocated to 11 experimental groups (n = 3): (i) PBS with both 660 and 780 nm laser irradiation as a NIR laser irradiation control group, (ii) BP@MFL as a drug carrier control group, (iii) RV as a free drug control group, (iv) doxorubicin (DOX) as a well-known anticancer drug control group, (v) RV/CAT-BP@MFL as a chemotherapy group, (vi) CAT-BP@MFL with 660 nm laser irradiation as an enhanced PDT group, (vii) CAT-BP@MFL with 780 nm laser irradiation as a PTT group, (viii) RV/CAT-BP@MFL with 660 nm laser irradiation as a chemotherapy/ enhanced PDT group, (ix) RV/CAT-BP@MFL with 780 nm laser irradiation as a chemotherapy/PTT group, (x) CAT-BP@ MFL with both 660 and 780 nm laser irradiation as a PTT/ enhanced PDT group, and (xi) RV/CAT-BP@MFL with both 660 and 780 nm laser irradiation as a chemotherapy/PTT/ enhanced PDT group. Under the guidance of the above in vivo NIR fluorescence imaging results, the NIR laser could be adjusted flexibly and accurately and precisely focused on the tumor site. For the PTT therapy, the tumor was irradiated with a 780 nm laser at a power density of 0.6 W cm −2 for 5 min at 1 h postinjection, while for the PDT therapy, the tumor was illuminated with a 660 nm laser (0.1 W cm −2 ) for 15 min at 1.5 h postinjection. For demonstration of the photothermal performance of RV/CAT-BP@MFL within the tumor, the temperature elevations (ΔT) were measured using an infrared camera under NIR laser irradiation. As shown in Figure 4E ,F, the ΔT of PBS with 780 nm laser irradiation was only ∼4.2°C. Whereas ΔT of RV/CAT-BP@MFL with 780 nm laser irradiation was ∼15.9°C, which was almost the same as that of BP@MFL (ΔT: ∼17.1°C), demonstrating that the RV and CAT loading had little influence on the photothermal efficiency of RV/CAT-BP@MFL. Moreover, no obvious temperature changes of RV/CAT-BP@MFL with 660 nm laser irradiation (ΔT: ∼0.2°C) excluded the contribution of 660 nm laser to the photothermal effect under current laser power conditions.
The therapeutic efficacies of different treatments were obtained by measuring the tumor volumes every other day for 14 days using a digital caliper. As displayed in Figure 5A , in groups i and ii, the tumor volumes all increased rapidly during the treatment period, indicating that both NIR laser exposure alone and drug carrier itself exhibited negligible influence on tumor development. In groups iii and iv, free RV and free DOX had a negligible growth inhibitory effect, which was probably because of its rapid metabolization for free RV and poor tumor accumulation for free DOX as previously reported. 63, 64 In contrast to groups i−iv, groups v−xi all delayed the growth rate of tumors in mice. An improved therapeutic efficacy could be found in groups viii, ix, and x compared with groups v, vi, and vii, indicating that tumor ablation ability of dual combination therapy was more effective than that with any monomodal therapy. Inspiringly, group xi with triple-modal combination therapy of chemotherapy/PTT/enhanced PDT showed the most excellent tumor therapeutic effect. Additionally, the digital photographs of representative mice ( Figure 5B ) vividly evidenced a prominent therapeutic effect of RV/CAT-BP@ MFL with a triple-modal synergistic strategy. From Figure 5C , the survival rates of the control group and monotherapy group were lower than the multimodal synergistic therapy group. Moreover, during the treatment, no abnormal body weight variation ( Figure 5D ) was observed in any groups, indicating that there were no acute side effects in the combination regimens. At the 14th day, the mice were humanely sacrificed. Then, the tumors were surgically excised, sliced, and stained by hematoxylin and eosin (H&E) for pathological analyses. As shown in Figure 5E , histological evaluation of tumors verified that, in group xi, most cancer cells were destroyed and became necrotic. Whereas, for other groups, tumor cells mostly or partially maintained their normal morphology. Collectively, these above results demonstrated the RV/CAT-BP@MFL nanoplatform to be auspicious nanotheranostics for chemotherapy/PTT/O 2 -enhanced PDT synergistic cancer therapy in vivo.
3.7. Biocompatibility Evaluation. On the basis of the encouraging therapeutic outcomes, the in vivo biocompatibility of the RV/CAT-BP@MFL was investigated systematically. First, the hemolysis assay of rat red blood cells (RBC) was performed by using PBS and ultrapure H 2 O as the negative control and positive control, respectively. As displayed in Figure S20 , no significant hemolysis (<5%) appeared in the entire concentration range from 18.5 to 2400 μg BP equiv mL −1 when RV/CAT-BP@MFL was coincubated with RBC for 24 h at 37°C. It was indicative of the excellent blood compatibility of RV/CAT-BP@MFL.
Meanwhile, the hematological and serum biochemical analyses were employed to further reveal any possible toxicity of RV/CAT-BP@MFL. Important hematological biomarkers ( Figure S21 ) were examined, containing RBC, white blood cells (WBC), platelets (PLT), hemoglobin (HGB), RBC distribution width-SD (RDW-SD), hematocrit (HCT), mean platelet volume (MPV), mean corpuscular hemoglobin (MCH), RBC distribution width-CV (RDW-CV), lymphocyte (LYM), middle-sized cells (MID), mean corpuscular hemoglobin concentration (MCHC), neutrophils percentage (NEU %), lymphocyte percentage (LYM%), and middle-sized cells percentage (MID%). Compared to those in the control group, all the above hematological parameters of rats treated with RV/CAT-BP@MFL did not reveal any statistical differences, indicating that no significant infection or inflammation was induced. In addition, the standard serum biochemistry examination ( Figure S22 ) was performed. The liver function indices related to alanine aminotransferase (ALT), aspartate aminotransferase (AST), and kidney functions revealed by blood urea nitrogen (BUN) and creatinine (CREA) did not show statistical differences between saline-treated and RV/ CAT-BP@MFL-treated rats, thereby suggesting negligible hepatic toxicity or kidney disorder. In addition, major organs (heart, liver, spleen, lung, and kidney) of mice using different treatment regimens were harvested for hematoxylin and eosin ACS Applied Nano Materials Article (H&E) stained histological study. As displayed in Figure S23 , there were no apparent histological abnormalities in these major organs, demonstrating that our theranostic reagent had no observable off-target damage to the normal organs. Collectively, the good biosafety set a solid foundation for the future clinical translation of the developed RV/CAT-BP@ MFL.
CONCLUSIONS
In summary, we described a versatile all-in-one theranostic nanoplatform based on functional liposome-stabilized BP for the tumor-targeted fluorescence imaging and imaging-guided photothermally maneuvered drug delivery and O 2 self-enriched photodynamic multiple therapy. In this study, the MFL containing targeting elements and imaging units were prepared and then coated around BP to improve the stability of BP nanosheets in the physiological environments. Furthermore, to obtain the ability of multiple therapy, RV (as an anticancer drug) and CAT (as a O 2 -evolving agent) were loaded on the surface of BP nanosheets before the coating processes of MFL. The obtained all-in-one nanoplatform (RV/CAT-BP@MFL) possessed excellent stability, good photocontrolled release behavior of the drug, high photothermal conversion efficiency, and enhanced singlet oxygen release efficiency. In vitro studies showed that the RV/CAT-BP@MFL displayed folate receptortargeted delivery, tumor hypoxia relief, and synergistic inhibition of tumor cell growth. Moreover, the in vivo results on tumor-bearing mice demonstrated that the nanoplatform could efficiently suppress the tumor growth with a single dose i.v. injection. Additionally, no appreciable toxicity and good biocompatibility were observed based on the hematological, serum biochemical, and histological analyses. Such a versatile all-in-one nanoplatform that integrates various functions including targeted fluorescence imaging, photothermally maneuvered drug delivery, and O 2 -enhanced PDT will be expected to have the potential to translate to clinical practice.
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